IMMUNOTHERAPY: A RICH HISTORY OF DISCOVERY & INNOVATION
Dr. Tak Mak clones the T-cell receptor.
Dr. Tak Mak demonstrates that CTLA4 (protein receptor) is a key regulatory checkpoint in the immune system.
Dr. Pamela Ohashi (above) and Dr. Linh Nguyen demonstrate that tumour-specific T-cells exist and are capable of mounting a response against tumours.
Dr. Pamela Ohashi, Dr. Linh Nguyen (above) and Patty Yen travel to Dr. Steven Rosenberg’s lab in the U.S. to learn techniques to grow tumour-specific T-cells.
Dr. Pamela Ohashi, Dr. Brad Nelson, Dr. Réjean Lapointe and Dr. Jonathan Bramson found the Canadian Cancer Immunotherapy Consortium.
Immune Therapy Program launches at Princess Margaret Cancer Centre.
First adoptive T-cell therapy clinical trial opens in Canada at The Princess Margaret.
Clinical leadership expandes with Dr. Lillian Siu joining the immunotherapy program.
Over 180 active immunotherapy clinical trials are underway at The Princess Margaret, including Canada’s first gene-engineered T-cell trial.
Drs. Naoto Hirano and Marcus Butler treat the first patient with cells engineered to attack tumours, a first in Canada.